Summary
Mycobacterium tuberculosis is one of the most successful pathogens affecting humankind: around 9 million people develop tuberculosis every year, resulting in 1.4 million deaths. Most people mount an immune response that is sufficient to control initial infection but they remain susceptible to reinfection or reactivation disease in later life. Immunological evidence suggests that up to two billion people worldwide may harbour latent tuberculosis, with a ten percent lifetime risk of developing active disease. The development of improved drugs, diagnostics and vaccines is central to the WHO End-TB strategy, which aims by 2035 for a:
95% reduction in TB deaths compared with 2015.
90% reduction in TB incidence rate compared with 2015.
Zero TB-affected families facing catastrophic costs due to TB
The aim of our research is to understand the host-pathogen interactions underlying the complex biology of tuberculosis infection, and to exploit this understanding for development of improved tools for disease control. We use genome-based biology, taking advantage of the availability of mycobacterial sequence data, techniques for mutagenesis and expression profiling, and the natural diversity of clinical isolates. We are investigating different ways to deliver anti-TB drugs, the potential of anti-microbial peptides, and host-directed therapies to improve TB treatment. We are also analysing how mycobacteria grow and divide, using microfluidics-based single cell analysis and time-lapse video microscopy.
I am a founder member of the MRC Centre for Molecular Bacteriology and Infection, and the Centre for Integrative Systems Biology and Bioinformatics.
I make significant contributions to undergraduate teaching within the Faculty of Medicine and was awarded a Certificate of Advanced Studies in Learning and Teaching by the college in 2003. He is currently Topic leader for Infection and Immunity for Phase 1 of the MBBS programme and co-lead for the Targeting Antimicrobial Resistance module in year 3 of the BSc in Medical Biosciences. He is Director of the Wellcome Trust funded 4-year PhD programme in the Molecular and Cellular Basis of Infection, and Editor-in-Chief of the journal Tuberculosis.
Publications
Journals
Rao KU, Henderson DI, Krishnan N, et al., 2021, A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy., Sci Rep, Vol:11
Asai M, Sheehan G, Li Y, et al., 2021, Innate immune responses of Galleria mellonella to Mycobacterium bovis BCG challenge identified using proteomic and molecular approaches, Frontiers in Cellular and Infection Microbiology, ISSN:2235-2988
Alzahabi KH, Usmani O, Georgiou TK, et al., 2020, Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies, Emerging Topics in Life Sciences, Vol:4, ISSN:2397-8554, Pages:581-600
Asai M, Li Y, Spiropoulos J, et al., 2020, A novel biosafety level 2 compliant tuberculosis infection model using a ΔleuDΔpanCD double auxotroph of Mycobacterium tuberculosis H37Rv and Galleria mellonella, Virulence, Vol:11, ISSN:2150-5594, Pages:811-824
Jégouzo SAF, Nelson C, Hardwick T, et al., 2020, Mammalian lectin arrays for screening host–microbe interactions, Journal of Biological Chemistry, Vol:295, ISSN:0021-9258, Pages:4541-4555